{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:21:51Z","timestamp":1783948911274,"version":"3.55.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-022-02840-9","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T04:03:14Z","timestamp":1653019394000},"page":"1903-1913","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Diagnostic impact of 18F-FDG PET\/CT imaging on the detection of immune-related adverse events in patients treated with immunotherapy"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4187-755X","authenticated-orcid":false,"given":"Gamze","family":"Tatar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6ksel","family":"Al\u00e7in","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilay","family":"Sengul Samanci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zge","family":"Erol Fenercioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ediz","family":"Beyhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tevfik Fikret","family":"Cermik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,20]]},"reference":[{"key":"2840_CR1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.canlet.2015.10.009","volume":"370","author":"H Tang","year":"2016","unstructured":"Tang H, Qiao J, Fu YX. Immunotherapy and tumor microenvironment. Cancer Lett. 2016;370:85\u201390. https:\/\/doi.org\/10.1016\/j.canlet.2015.10.009.","journal-title":"Cancer Lett"},{"key":"2840_CR2","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/nrclinonc.2014.174","volume":"11","author":"SA Rosenberg","year":"2014","unstructured":"Rosenberg SA. Decade in review-cancer immunotherapy: entering the mainstream of cancer treatment. Nat Rev Clin Oncol. 2014;11:630\u20132. https:\/\/doi.org\/10.1038\/nrclinonc.2014.174.","journal-title":"Nat Rev Clin Oncol"},{"key":"2840_CR3","doi-asserted-by":"publisher","first-page":"127","DOI":"10.4103\/apjon.apjon_4_17","volume":"4","author":"J Dine","year":"2017","unstructured":"Dine J, Gordon R, Shames Y, Kasler MK, Barton-Burke M. Immune checkpoint inhibitors: an innovation in immunotherapy for the treatment and management of patients with cancer. Asia Pac J Oncol Nurs. 2017;4:127\u201335. https:\/\/doi.org\/10.4103\/apjon.apjon_4_17.","journal-title":"Asia Pac J Oncol Nurs"},{"key":"2840_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s41747-020-00190-1","volume":"4","author":"M Unterrainer","year":"2020","unstructured":"Unterrainer M, Ruzicka M, Fabritius MP, Mittlmeier LM, Winkelmann M, R\u00fcbenthaler J, et al. PET\/CT imaging for tumour response assessment to immunotherapy: current status and future directions. Eur Radiol Exp. 2020;4:63. https:\/\/doi.org\/10.1186\/s41747-020-00190-1.","journal-title":"Eur Radiol Exp"},{"key":"2840_CR5","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s12094-020-02397-5","volume":"23","author":"R Park","year":"2021","unstructured":"Park R, Lopes L, Saeed A. Anti-PD-1\/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis. Clin Transl Oncol. 2021;23:100\u20139. https:\/\/doi.org\/10.1007\/s12094-020-02397-5.","journal-title":"Clin Transl Oncol"},{"key":"2840_CR6","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1007\/s00259-017-3870-6","volume":"45","author":"H Anwar","year":"2018","unstructured":"Anwar H, Sachpekidis C, Winkler J, Kopp-Schneider A, Haberkorn U, Hassel JC, et al. Absolute number of new lesions on 18F-FDG PET\/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. Eur J Nucl Med Mol Imaging. 2018;45:376\u201383. https:\/\/doi.org\/10.1007\/s00259-017-3870-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2840_CR7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.cell.2020.03.001","volume":"181","author":"EW Weber","year":"2020","unstructured":"Weber EW, Maus MV, Mackall CL. The emerging landscape of immune cell therapies. Cell. 2020;181:46\u201362. https:\/\/doi.org\/10.1016\/j.cell.2020.03.001.","journal-title":"Cell"},{"key":"2840_CR8","doi-asserted-by":"publisher","first-page":"e272","DOI":"10.1097\/RLU.0000000000002453","volume":"44","author":"T Nobashi","year":"2019","unstructured":"Nobashi T, Baratto L, Reddy SA, Srinivas S, Toriihara A, Hatami N, et al. Predicting response to immunotherapy by evaluating tumors, lymphoid cell-rich organs, and immune-related adverse events using FDG PET\/CT. Clin Nucl Med. 2019;44:e272\u20139. https:\/\/doi.org\/10.1097\/RLU.0000000000002453.","journal-title":"Clin Nucl Med"},{"key":"2840_CR9","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/j.semnuclmed.2020.06.001","volume":"50","author":"SY Cho","year":"2020","unstructured":"Cho SY, Huff DT, Jeraj R, Albertini MR. FDG PET\/CT for assessment of immune therapy: opportunities and understanding pitfalls. Semin Nucl Med. 2020;50:518\u201331. https:\/\/doi.org\/10.1053\/j.semnuclmed.2020.06.001.","journal-title":"Semin Nucl Med"},{"key":"2840_CR10","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3389\/fphar.2017.00730","volume":"8","author":"PF Wang","year":"2017","unstructured":"Wang PF, Chen Y, Song SY, Wang TJ, Ji WJ, Li SW, et al. Immune-related adverse events associated with anti-PD-1\/PD-L1 treatment for malignancies: a meta-analysis. Front Pharmacol. 2017;8:730. https:\/\/doi.org\/10.3389\/fphar.2017.00730.","journal-title":"Front Pharmacol"},{"key":"2840_CR11","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1093\/cid\/ciy1025","volume":"69","author":"JA Fishman","year":"2019","unstructured":"Fishman JA, Hogan JI, Maus MV. Inflammatory and infectious syndromes associated with cancer immunotherapies. Clin Infect Dis. 2019;69:909\u201320. https:\/\/doi.org\/10.1093\/cid\/ciy1025.","journal-title":"Clin Infect Dis"},{"key":"2840_CR12","doi-asserted-by":"publisher","first-page":"4928","DOI":"10.3390\/cancers13194928","volume":"13","author":"JM L\u2019Orphelin","year":"2021","unstructured":"L\u2019Orphelin JM, Varey E, Khammari A, Dreno B, Dompmartin A. Severe late-onset grade III\u2013IV adverse events under immunotherapy: a retrospective study of 79 cases. Cancers (Basel). 2021;13:4928. https:\/\/doi.org\/10.3390\/cancers13194928.","journal-title":"Cancers (Basel)"},{"key":"2840_CR13","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","volume":"28","author":"L Khoja","year":"2017","unstructured":"Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017;28:2377\u201385. https:\/\/doi.org\/10.1093\/annonc\/mdx286.","journal-title":"Ann Oncol"},{"key":"2840_CR14","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s00261-019-01935-2","volume":"44","author":"F Alessandrino","year":"2019","unstructured":"Alessandrino F, Sahu S, Nishino M, Adeni AE, Tirumani SH, Shinagare AB, et al. Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor. Abdom Radiol. 2019;44:1917\u201327. https:\/\/doi.org\/10.1007\/s00261-019-01935-2.","journal-title":"Abdom Radiol"},{"key":"2840_CR15","doi-asserted-by":"publisher","first-page":"20200663","DOI":"10.1259\/bjr.20200663","volume":"94","author":"MA Anderson","year":"2021","unstructured":"Anderson MA, Kurra V, Bradley W, Kilcoyne A, Mojtahed A, Lee SI. Abdominal immune-related adverse events: detection on ultrasonography, CT, MRI and 18F-fluorodeoxyglucose positron emission tomography. Br J Radiol. 2021;94:20200663. https:\/\/doi.org\/10.1259\/bjr.20200663.","journal-title":"Br J Radiol"},{"key":"2840_CR16","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2217\/imt-2018-0146","volume":"11","author":"N Lang","year":"2019","unstructured":"Lang N, Dick J, Slynko A, Schulz C, Dimitrakopoulou-Strauss A, Sachpekidis C, et al. Clinical significance of signs of autoimmune colitis in 18F-fluorodeoxyglucose positron emission tomography-computed tomography of 100 stage-IV melanoma patients. Immunotherapy. 2019;11:667\u201376. https:\/\/doi.org\/10.2217\/imt-2018-0146.","journal-title":"Immunotherapy"},{"key":"2840_CR17","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.2217\/imt-2019-0077","volume":"11","author":"A C\u01celug\u01cereanu","year":"2019","unstructured":"C\u01celug\u01cereanu A, Rompteaux P, Bohelay G, Goldfarb L, Barrau V, Cucherousset N, et al. Late onset of nivolumab-induced severe gastroduodenitis and cholangitis in a patient with stage IV melanoma. Immunotherapy. 2019;11:1005\u201313. https:\/\/doi.org\/10.2217\/imt-2019-0077.","journal-title":"Immunotherapy"},{"key":"2840_CR18","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1093\/annonc\/mdx403","volume":"28","author":"M Collins","year":"2017","unstructured":"Collins M, Michot JM, Danlos FX, Mussini C, Soularue E, Mateus C, et al. Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. Ann Oncol. 2017;28:2860\u20135. https:\/\/doi.org\/10.1093\/annonc\/mdx403.","journal-title":"Ann Oncol"},{"key":"2840_CR19","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1158\/2326-6066.CIR-15-0102","volume":"3","author":"SH Tirumani","year":"2015","unstructured":"Tirumani SH, Ramaiya NH, Keraliya A, Bailey ND, Ott PA, Hodi FS, et al. Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res. 2015;3:1185\u201392. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0102.","journal-title":"Cancer Immunol Res"},{"key":"2840_CR20","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/s41379-018-0013-y","volume":"31","author":"Y Zen","year":"2018","unstructured":"Zen Y, Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol. 2018;31:965\u201373. https:\/\/doi.org\/10.1038\/s41379-018-0013-y.","journal-title":"Mod Pathol"},{"key":"2840_CR21","doi-asserted-by":"publisher","first-page":"204062232097699","DOI":"10.1177\/2040622320976996","volume":"12","author":"S Zhang","year":"2021","unstructured":"Zhang S, Zhou Z, Wang L, Li M, Zhang F, Zeng X. Rheumatic immune-related adverse events associated with immune checkpoint inhibitors compared with placebo in oncologic patients: a systemic review and meta-analysis. Ther Adv Chronic Dis. 2021;12:2040622320976996. https:\/\/doi.org\/10.1177\/2040622320976996.","journal-title":"Ther Adv Chronic Dis"},{"key":"2840_CR22","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1007\/s00259-020-04815-w","volume":"47","author":"A Iravani","year":"2020","unstructured":"Iravani A, Osman MM, Weppler AM, Wallace R, Galligan A, Lasocki A, et al. FDG PET\/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment. Eur J Nucl Med Mol Imaging. 2020;47:2776\u201386. https:\/\/doi.org\/10.1007\/s00259-020-04815-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2840_CR23","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","volume":"2","author":"M Nishino","year":"2016","unstructured":"Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2:1607\u201316. https:\/\/doi.org\/10.1001\/jamaoncol.2016.2453.","journal-title":"JAMA Oncol"},{"key":"2840_CR24","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1097\/RLU.0000000000001758","volume":"42","author":"M Zhang","year":"2017","unstructured":"Zhang M, Schembri G. Nivolumab-induced development of pulmonary sarcoidosis in renal cell carcinoma. Clin Nucl Med. 2017;42:728\u20139. https:\/\/doi.org\/10.1097\/RLU.0000000000001758.","journal-title":"Clin Nucl Med"},{"key":"2840_CR25","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1016\/j.chest.2015.10.082","volume":"149","author":"FX Danlos","year":"2016","unstructured":"Danlos FX, Pag\u00e8s C, Baroudjian B, Vercellino L, Battistella M, Mimoun M, et al. Nivolumab-induced sarcoid-like granulomatous reaction in a patient with advanced melanoma. Chest. 2016;149:e133\u20136. https:\/\/doi.org\/10.1016\/j.chest.2015.10.082.","journal-title":"Chest"},{"key":"2840_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cpet.2019.08.006","volume":"15","author":"K Prigent","year":"2020","unstructured":"Prigent K, Aide N. 18F-Fludeoxyglucose PET\/computed tomography for assessing tumor response to immunotherapy and detecting immune-related side effects: a checklist for the PET reader. PET Clin. 2020;15:1\u201310. https:\/\/doi.org\/10.1016\/j.cpet.2019.08.006.","journal-title":"PET Clin"},{"key":"2840_CR27","doi-asserted-by":"publisher","first-page":"260","DOI":"10.2967\/jnmt.117.204933","volume":"46","author":"N Eshghi","year":"2018","unstructured":"Eshghi N, Garland LL, Nia E, Betancourt R, Krupinski E, Kuo PH. 18F-FDG PET\/CT can predict development of thyroiditis due to immunotherapy for lung cancer. J Nucl Med Technol. 2018;46:260\u20134. https:\/\/doi.org\/10.2967\/jnmt.117.204933.","journal-title":"J Nucl Med Technol"},{"key":"2840_CR28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","volume":"4","author":"R Barroso-Sousa","year":"2018","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018;4:173\u201382. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3064.","journal-title":"JAMA Oncol"},{"key":"2840_CR29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.acra.2016.08.005","volume":"24","author":"JW Wachsmann","year":"2017","unstructured":"Wachsmann JW, Ganti R, Peng F. Immune-mediated disease in ipilimumab immunotherapy of melanoma with FDG PET-CT. Acad Radiol. 2017;24:111\u20135. https:\/\/doi.org\/10.1016\/j.acra.2016.08.005.","journal-title":"Acad Radiol"},{"key":"2840_CR30","doi-asserted-by":"publisher","first-page":"20190832","DOI":"10.1259\/bjr.20190832","volume":"93","author":"N Gandy","year":"2020","unstructured":"Gandy N, Arshad MA, Wallitt KL, Dubash S, Khan S, Barwick TD. Immunotherapy-related adverse effects on 18F-FDG PET\/CT imaging. Br J Radiol. 2020;93:20190832. https:\/\/doi.org\/10.1259\/bjr.20190832.","journal-title":"Br J Radiol"},{"key":"2840_CR31","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1097\/RLU.0000000000002692","volume":"44","author":"JP Das","year":"2019","unstructured":"Das JP, Halpenny D, Do RK, Ulaner GA. Focal immunotherapy-induced pancreatitis mimicking metastasis on FDG PET\/CT. Clin Nucl Med. 2019;44:836\u20137. https:\/\/doi.org\/10.1097\/RLU.0000000000002692.","journal-title":"Clin Nucl Med"},{"key":"2840_CR32","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1053\/j.ajkd.2019.03.433","volume":"74","author":"R Shingarev","year":"2019","unstructured":"Shingarev R, Glezerman IG. Kidney complications of immune checkpoint inhibitors: a review. Am J Kidney Dis. 2019;74:529\u201337. https:\/\/doi.org\/10.1053\/j.ajkd.2019.03.433.","journal-title":"Am J Kidney Dis"},{"key":"2840_CR33","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1186\/s40425-019-0820-9","volume":"7","author":"D Qualls","year":"2019","unstructured":"Qualls D, Seethapathy H, Bates H, Tajmir S, Heidari P, Endres P, et al. Positron emission tomography as an adjuvant diagnostic test in the evaluation of checkpoint inhibitor-associated acute interstitial nephritis. J Immunother Cancer. 2019;7:356. https:\/\/doi.org\/10.1186\/s40425-019-0820-9.","journal-title":"J Immunother Cancer"},{"key":"2840_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002890corr1","volume":"9","author":"AC Guidon","year":"2021","unstructured":"Guidon AC, Burton LB, Chwalisz BK, Hillis J, Schaller TH, Amato AA, et al. Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer. 2021;9: e002890. https:\/\/doi.org\/10.1136\/jitc-2021-002890corr1.","journal-title":"J Immunother Cancer"},{"key":"2840_CR35","doi-asserted-by":"publisher","first-page":"579","DOI":"10.4070\/kcj.2021.0089","volume":"51","author":"A Zarifa","year":"2021","unstructured":"Zarifa A, Kim JW, Lopez-Mattei J, Palaskas N, Iliescu C, Kim PY. Cardiac toxicities associated with immune checkpoints inhibitors: mechanisms. Manif Manag Korean Circ J. 2021;51:579\u201397. https:\/\/doi.org\/10.4070\/kcj.2021.0089.","journal-title":"Manif Manag Korean Circ J"},{"key":"2840_CR36","doi-asserted-by":"publisher","first-page":"354","DOI":"10.2478\/raon-2021-0019","volume":"55","author":"T Mesti","year":"2021","unstructured":"Mesti T, Ceplak Mencin V, Mileva Boshkoska B, Ocvirk J. Adverse events during immunotherapy in Slovenian patients with metastatic melanoma reveal a positive correlation with better treatment outcomes. Radiol Oncol. 2021;55:354\u201361. https:\/\/doi.org\/10.2478\/raon-2021-0019.","journal-title":"Radiol Oncol"},{"key":"2840_CR37","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","volume":"2","author":"CF Friedman","year":"2016","unstructured":"Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2:1346\u201353. https:\/\/doi.org\/10.1001\/jamaoncol.2016.1051.","journal-title":"JAMA Oncol"},{"key":"2840_CR38","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","volume":"4","author":"K Haratani","year":"2018","unstructured":"Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, et al. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol. 2018;4:374\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2017.2925.","journal-title":"JAMA Oncol"},{"key":"2840_CR39","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/07357907.2021.1994586","volume":"40","author":"T Yamamoto","year":"2022","unstructured":"Yamamoto T, Ito T, Hase T, Ishigami M, Mizuno K, Yamamoto K, et al. Immune-related liver injury is a poor prognostic factor in patients with nonsmall cell lung cancer treated with immune checkpoint inhibitors. Cancer Investig. 2022;40:189\u201398. https:\/\/doi.org\/10.1080\/07357907.2021.1994586.","journal-title":"Cancer Investig"},{"key":"2840_CR40","doi-asserted-by":"publisher","first-page":"e893","DOI":"10.1016\/j.cllc.2018.08.008","volume":"19","author":"DH Owen","year":"2018","unstructured":"Owen DH, Wei L, Bertino EM, Edd T, Villalona-Calero MA, He K, et al. Incidence, risk factors, and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer. Clin Lung Cancer. 2018;19:e893\u2013900. https:\/\/doi.org\/10.1016\/j.cllc.2018.08.008.","journal-title":"Clin Lung Cancer"},{"key":"2840_CR41","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12916-020-01549-2","volume":"18","author":"X Zhou","year":"2020","unstructured":"Zhou X, Yao Z, Yang H, Liang N, Zhang X, Zhang F. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med. 2020;18:87. https:\/\/doi.org\/10.1186\/s12916-020-01549-2.","journal-title":"BMC Med"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-022-02840-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-022-02840-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-022-02840-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T16:40:07Z","timestamp":1661532007000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-022-02840-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,20]]},"references-count":41,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["2840"],"URL":"https:\/\/doi.org\/10.1007\/s12094-022-02840-9","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,20]]},"assertion":[{"value":"9 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the University of Health Sciences, Istanbul Training and Research Hospital, Clinical Research Ethics Committee (date 10.09.2021, number 2915).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This retrospective study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors did not conduct research involving animals.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Written informed consent was obtained from all participants when they enrolled for PET\/CT imaging.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Patients signed informed consent regarding publishing their data and PET\/CT images.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}